Bacterial infections in a pediatric cohort of primary and acquired complement deficiencies

Pediatr Rheumatol Online J. 2020 Sep 24;18(1):74. doi: 10.1186/s12969-020-00467-0.

Abstract

Background: Acquired complement deficiency can occur in the setting of autoimmune syndromes, such as systemic lupus erythematosus (SLE), with very low or, occasionally, undetectable C3 levels. Based on inherited complement defects, patients with transiently low complement may be at similar risk for serious bacterial infection, but the degree of risk related to C3 level and temporal association is unknown.

Methods: We performed a retrospective study including pediatric patients with undetectable total complement activity or absent individual complement components measured at our institution from 2002 to 2018. We assessed annual rate of serious bacterial infection (SBI) defined as requiring hospitalization and/or parenteral antibiotics by manual chart review. Among included SLE patients, we assessed the 30-day probability of SBI for given C3 measurements using a logistic regression model to determine risk. Primary complement deficiency was analyzed for SBI rate as comparison. Covariates included age, level of immune suppression and history of lupus nephritis.

Results: Acquired complement deficiency secondary to SLE-related disease [n = 44] was the most common underlying diagnosis associated with depressed complement levels and were compared to a cohort of primary complement deficient patients [n = 18]. SBI per 100 person-years and cohort demographics were described in parallel. Our logistic regression analysis of pediatric patients with SLE showed low C3 level was temporally associated with having an SBI event. Given equivalent immunosuppression, patients with an SBI had lower C3 levels at the beginning of the observation period relative to patients without SBI.

Conclusion: Pediatric patients with the diagnosis of SLE can develop very low C3 levels that associate with risk of serious bacterial infection comparable to that of patients with primary complement deficiency. Patients prone to severe complement consumption may particularly be at risk.

Keywords: Complement; Connective tissue disease; SLE; Systemic lupus Erythematosus.

MeSH terms

  • Administration, Intravenous
  • Adolescent
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Infections / drug therapy
  • Bacterial Infections / epidemiology*
  • Bacterial Infections / immunology
  • Child
  • Child, Preschool
  • Cohort Studies
  • Complement C3 / deficiency*
  • Complement C3 / immunology
  • Female
  • Hereditary Complement Deficiency Diseases / epidemiology*
  • Hereditary Complement Deficiency Diseases / immunology
  • Hospitalization / statistics & numerical data
  • Humans
  • Immunocompromised Host
  • Immunosuppressive Agents / therapeutic use
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / epidemiology*
  • Lupus Erythematosus, Systemic / immunology
  • Lupus Nephritis / epidemiology
  • Lupus Nephritis / immunology
  • Male
  • Retrospective Studies
  • Severity of Illness Index

Substances

  • Anti-Bacterial Agents
  • Complement C3
  • Immunosuppressive Agents